Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naïve non-small cell lung cancer: An under-recognized phenomenon.
Xiao Chu, Yuyin Xu, Ye Li...
https://pubmed.ncbi.nlm.nih.gov/35609408/Actively Recruiting
Led by Fudan University · Updated on 2024-04-23
50
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are investigating neuroendocrine transformation NET in patients with non-small cell lung cancer NSCLC who have dual inactivation of the RB1 and TP53 genes. This transformation, particularly from EGFR-mutant lung adenocarcinoma to small cell lung cancer, is a rare cause of resistance to tyrosine kinase inhibitors TKIs. The study aims to understand the risk and occurrence of NET in this specific NSCLC subgroup, as well as to collect baseline pathological, clinical, and imaging data to monitor disease progression over time. This observational study involves systematically following NSCLC patients with confirmed dual RB1TP53 inactivation through pathological testing. Patients will receive standard systemic treatments such as chemotherapy, targeted therapy, or immunotherapy and undergo regular follow-ups. When disease progression is detected, further biopsies of progressing lesions will be conducted as part of the study protocol. Biological samples including blood and tissue will be collected before and during follow-up treatment to support research objectives. Participants will be monitored over a period of up to 10 years to assess the rate of neuroendocrine transformation. Researchers will review imaging, pathology, and clinical data regularly, with evaluations including driver gene testing and functional status assessments. Safety and treatment effects will be observed alongside the main outcome measures. The study requires informed consent and adherence to contraception guidelines during participation, ensuring continuous data collection and patient care throughout the follow-up period.
CONDITIONS
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
X
Xiao Chu, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fudan University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years after enrollment
Participants are observed over time to track neuroendocrine transformation and disease progression.
Regular follow-up visits with blood and biopsy sample collection during disease progression
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Xiao Chu, Yuyin Xu, Ye Li...
https://pubmed.ncbi.nlm.nih.gov/35609408/Fudan University
Lead Sponsor